Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott India Confident Despite Phensedyl Problems

This article was originally published in PharmAsia News

Executive Summary

Abbott India, part of the US-based global healthcare company, says it is confident about the safety of its popular cough syrup Phensedyl, after it was reported that a government laboratory test found a sample bottle allegedly contained an excessive amount of codeine.

You may also be interested in...

Abbott's Top India Product Phensedyl Nosedives As India Faces Severe Codeine Shortage

MUMBAI - Drug maker Abbott may have leaped to the lead position in the Indian market with the much-hyped acquisition of Piramal Healthcare's formulations business, but data shows a three-fold sales decline of its lead brand, the cough syrup Phensedyl (chlorpheniramine/codeine), in the last eight months

Share Fillip As Indian Pharma Crests US Regulatory Hump

For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.

Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial

Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts